Trial results

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

NCT06651177 on ClinicalTrials.gov · last registry update 2026-08-11

An unusually large phase 2: 310 participants, more than double the 114 typical for the stage. Due to report 30 September 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: 6-month retention in BUP treatment. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

RECRUITING

Phase

P2

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

T. John Winhusen, PhD

Sponsor type

Other

Enrollment

310

Started

2026-01-29

Primary completion

2027-09-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

6-month retention in BUP treatment

Conditions studied

Opioid Use Disorder · Opioid Use Disorder, Moderate · Opioid Use Disorder, Severe

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.